The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

Completed · Not applicable · Has a placebo group

Conditions studied: Mild Cognitive Impairment, Subjective Memory Impairment

In brief

There is a dearth of research which takes a multi-compound approach to dietary interventions, in humans, aimed at improving outcome measures of cognition. Animal research in particular points towards fatty acids and flavonoids having a potentiating effect on each other, and possibly even being synergistic. Thus, study products will be administered in the present trial comprising both of these compounds, with a view to investigating their potential effects on cognition in older adults with mild cognitive impairment (MCI) or subjective memory impairment (SMI).

Key facts

Study ID

NCT02525198

Run by

University of East Anglia

People needed

259

Starts

2015-08-01

Expected to finish

2018-03-31

Last updated by the study team

2024-05-14

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female, aged ≥ 55 years
• Mild cognitive impairment (MCI) or subjective memory impairment (SMI) with no indication of clinical dementia or depression
• Willing and able to provide written informed consent.
• Understands and is willing and able to comply with all study procedures.
• Fluent in written and spoken English.
• In good general health including blood biochemical, haematological and urinalysis within the normal range at screening (as judged by the clinical advisor)
• Normal, or corrected to normal vision and hearing
• Right handed, for MRI
• Stable use of any prescribed medication for at least four weeks

You may not qualify if…

• Diagnosis of Alzheimer's disease (AD) or other form of dementia or significant neurological disorder
• Parent or sibling who developed premature dementia <60y (suggestive of a familial monogenic form of cognitive decline)
• Past history or MRI evidence of brain damage including significant trauma, stroke, learning difficulties or serious neurological disorder, including loss of consciousness > 24 hours
• History of alcohol or drug dependency within the last 2 years
• Other clinically diagnosed psychiatric disorder likely to affect the cognitive measures (as judged by clinical adviser)
• Existing diagnosed gastrointestinal disorders likely to impact on absorption of flavonoids and fatty acids (as judged by clinical adviser)
• Major cardiovascular event, e.g. myocardial infarction or stroke, in the last 12 months
• Carotid stents or severe stenosis
• Known allergy to fish or any other component in the intervention supplements
• Existing medical conditions likely to affect the study measures (as judged by clinical adviser)
• Uncontrolled hypertension (Systolic Blood Pressure (SBP) >140mmHg, Diastolic Blood Pressure (DBP) >90mmHg)
• BMI >40kg/m2

Where it is running

• Beckman Institute, University of Illinois — Urbana, Illinois, United States
• Centre for Human Psychopharmacology, Swinburne Univerity of Technology — Melbourne, Victoria, Australia
• Department of Nutrition, University of East Anglia — Norwich, Norfolk, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.